statistiche ricercatore

Continente	#
NA - Nord America	789
EU - Europa	497
AS - Asia	377
SA - Sud America	68
AF - Africa	13
Continente sconosciuto - Info sul continente non disponibili	2
Totale	1.746

Nazione	#
US - Stati Uniti d'America	771
PL - Polonia	165
CN - Cina	142
SG - Singapore	118
IT - Italia	78
UA - Ucraina	61
BR - Brasile	59
DE - Germania	48
HK - Hong Kong	39
FI - Finlandia	36
GB - Regno Unito	23
VN - Vietnam	21
BE - Belgio	16
IE - Irlanda	16
TR - Turchia	15
IN - India	14
CA - Canada	10
CZ - Repubblica Ceca	9
FR - Francia	8
ZA - Sudafrica	8
NL - Olanda	7
RU - Federazione Russa	7
ID - Indonesia	5
MX - Messico	5
AR - Argentina	4
AT - Austria	4
IQ - Iraq	4
JP - Giappone	4
NO - Norvegia	4
BD - Bangladesh	3
ES - Italia	3
GR - Grecia	3
SE - Svezia	3
CO - Colombia	2
DZ - Algeria	2
EC - Ecuador	2
EU - Europa	2
IL - Israele	2
KR - Corea	2
MA - Marocco	2
AE - Emirati Arabi Uniti	1
AM - Armenia	1
AZ - Azerbaigian	1
CH - Svizzera	1
DO - Repubblica Dominicana	1
HN - Honduras	1
JM - Giamaica	1
KE - Kenya	1
KG - Kirghizistan	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LT - Lituania	1
LV - Lettonia	1
MD - Moldavia	1
PK - Pakistan	1
PT - Portogallo	1
RO - Romania	1
SA - Arabia Saudita	1
VE - Venezuela	1
Totale	1.746

Nome	#
Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance	263
High sulfation and a high molecular weight are important for anti-hepcidin activity of heparin	184
Natural Histogel-Based Bio-Scaffolds for Sustaining Angiogenesis in Beige Adipose Tissue	180
Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo	177
A novel pro-oncogenic mutated form of VEGFR2 modulates the activity of co-expressed wild-type receptor in melanoma	161
Evaluation of Paracellular Permeability in VEGFR2 Mutants Patient-Derived Organoid	139
A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis	128
Role of VEGFs in metabolic disorders	124
A novel VEGFR2 mutation has oncogenic potential in BRAF wild-type melanoma	121
VEGFR2 activation mediates the pro-angiogenic activity of BMP4	116
A novel VEGFR2 mutation has oncogenic potential in BRAF wild type melanoma	107
Identification and characterization of pro-oncogenic low frequency VEGFR2 mutations	86
Totale	1.786

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	172	0	0	0	0	0	30	20	24	27	32	22	17
2021/2022	116	9	17	1	8	3	7	5	7	4	19	11	25
2022/2023	90	13	6	4	5	6	25	0	5	17	0	3	6
2023/2024	148	10	4	14	18	6	27	7	19	23	3	1	16
2024/2025	324	11	4	3	56	22	18	21	17	33	19	66	54
2025/2026	334	62	47	47	80	72	26	0	0	0	0	0	0
Totale													1.786